VIVAZEN® Commends the Drug Enforcement Administration’s Decision to Schedule Synthetic 7-Hydroxymitragynine (7-OH) and Three Related Drugs
Botanical wellness leader supports decisive actions to get dangerous drugs out of hands of consumers and protect access to high-quality, natural botanical products
VIVAZEN®, the nation’s leading botanical wellness company, welcomes the Drug Enforcement Administration’s (DEA) decision to classify 7-hydroxymitragynine (7-OH) and three related drugs as Schedule I drug. 7-OH is a dangerous synthetic, lab-made drug that HHS and FDA have described as harmful and addictive. 7-OH has raised serious concerns for public health and consumer safety. This move critically distinguishes these harmful synthetic drugs and the natural botanical kratom.
“The DEA decisively addressed the real, tangible risks associated with 7-OH drugs, making consumers safer and the marketplace more transparent,” said Bryan Derr, Chief Operating Officer of VIVAZEN®. “VIVAZEN® was built on a commitment to providing consumers with effective wellness solutions, innovating responsibly, and above all, prioritizing transparency and quality. This critical move makes it easier for VIVAZEN® to uphold these same commitments without worrying that consumers could be tricked by duplicitous drugs marketing themselves as safe wellness solutions rather than the dangerous synthetic drugs they are.”
